Concepedia

Correlation Between the Response to Cetuximab Alone or in Combination With Irinotecan and the Activated/Phosphorylated Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer

Nicola Personeni, Alain Hendlisz, Julien Gallez, María Gómez Galdón, Denis Larsimont, J VANLAETHEM, N NAGY, M. Barette, M Paesmans, Fátima Cardoso

Seminars in Oncology · 2005 · 31 citations · 19 references

DOI

Concepts

References

19

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

, , +16

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

, , +17

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

, , +16

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Diana Graus-Porta, Roger R. Beerli, J.M. Daly et al. · The EMBO Journal · 1997 · 1.6K citations

, , +6